Telix Pharmaceuticals Limited (NASDAQ:TLX) is a top ASX stock, focusing on treatments for prostate and kidney cancer. TLX591, its prostate cancer therapy candidate, is in a phase three study called ProstACT. Telix dosed the first patient in part two of the study on December 8th, aiming to enroll 490 patients. Telix also received Medicare and Medicaid’s Transitional Pass-Through payment status for its prostate cancer imaging agent Gozellix, reporting $206 million in revenue for Q3 with imaging products driving sales.

Investors are urged to consider AI stocks with higher return potential and limited downside risk. For those seeking an affordable AI stock benefiting from Trump tariffs and onshoring, check out the recommended short-term AI stock. For more investment insights, explore the articles on 30 stocks expected to double in 3 years and 11 hidden AI stocks to consider. No disclosures in this publication.

Read more at Yahoo Finance: Telix Pharma (TLX) Makes Progress With New Study